Comparative effectiveness of SGLT2 sodium‐glucose cotransporter‐2 inhibitors and GLP‐1 glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study
Abstract Objective This study provides real-world evidence on the comparative effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM). Research Design and Methods This cohort study utilised electronic health records from TriNetX (1 April 2013 to 31 […]
Beauty Is Changing Its Game Plan for the Ozempic Era
From surgery to supplements, GLP-1 medications are radically evolving the beauty space. We unpack the latest innovations.
Opinion: Public health should embrace GLP-1 drugs without abandoning obesity prevention
Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to gain access to highly effective options. The implications for U.S. public health are vast. Read the rest…
Guggenheim Lifts PT on Pfizer Inc. (PFE) to $35 From $33, Keeps a Buy Rating
Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]
**Breaking Down the Cost of Healthcare: Medicare Beneficiaries to Reap Benefits from Falling Drug Prices**
Breaking Down the Cost of Healthcare: Medicare Beneficiaries to Reap Benefits from Falling Drug Prices The rising cost of prescription medications has been a pressing concern for many Americans, particularly those relying on Medicare for their healthcare coverage. For years, the prices of certain medications have continued to soar, leaving many individuals struggling to afford […]
Amphastar (AMPH) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Saturday, Nov. 8, 2025 at 12:16 p.m. ET Call participants Chief Commercial Officer — Dan Dischner Chief Financial Officer and Executive Vice President of Finance — William Peters Senior Vice President, Regulatory Affairs and Clinical Operations — Tony Marrs Need a quote from a Motley Fool analyst? Email [email protected] […]
Cal-Maine Foods (CALM) Q1 2026 Earnings Transcript
Image source: The Motley Fool. DATE Wednesday, Oct. 1, 2025 at 12:22 p.m. ET CALL PARTICIPANTS President and CEO — Sherman Miller Chief Financial Officer — Max Bowman Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Net Sales — $922.6 million, up 17.4%, driven by higher shell egg sales and prepared foods […]
Medpace (MEDP) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool. DATE Thursday, Oct. 23, 2025 at 1:37 p.m. ET CALL PARTICIPANTS President — August Troendle CFO — Kevin Brady Investor Relations — Jesse Geiger Investor Relations — Lauren Morris Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Revenue — $659.9 million, up 23.7% year-over-year, driven by higher […]
Corcept (CORT) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Tuesday, Nov. 4, 2025 at 7:26 p.m. ET Call participants Chief Executive Officer — Joseph K. Belanoff Chief Business Officer — Gary Robb President, Endocrinology — Sean Maduck Chief Development Officer — William Guyer Chief Financial Officer — Atabak Mokari Need a quote from a Motley Fool analyst? Email […]
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its blockbuster obesity drug, Wegovy (injectable semaglutide). The FDA filing seeks approval for a 7.2 mg dose of the drug, which Novo Nordisk claims provides an option for “greater weight loss potential” than what is currently being […]